Price
Financials
Standalone, Rs crore| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|
| Sales | -15 | 6 | 5 | 1 | 2 | 0 | 0 | 0 |
| Expenses | 110 | 9 | 8 | 618 | 13 | 2 | 2 | 1 |
| Operating Profit | -125 | -3 | -3 | -617 | -11 | -1 | -1 | -1 |
| OPM % | -54% | -69% | -102,843% | -492% | -251% | -293% | ||
| Other Income | -18 | 0 | 0 | -219 | 0 | 0 | 0 | 0 |
| Interest | 38 | 62 | 69 | 16 | 108 | 0 | 0 | 0 |
| Depreciation | 34 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Profit before tax | -215 | -81 | -88 | -868 | -134 | -17 | -17 | -17 |
| Tax % | 0% | 0% | 0% | 0% | -331% | 0% | 0% | 0% |
| Net Profit | -215 | -81 | -88 | -868 | 310 | -17 | -17 | -17 |
| EPS in Rs | -10.60 | -3.97 | -4.35 | -42.80 | 15.28 | -0.83 | -0.84 | -0.85 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 239 | 283 | 486 | 723 | 1,134 | 1,600 | 1,623 | 60 | 3 |
| Expenses | 192 | 231 | 400 | 602 | 973 | 1,337 | 1,765 | 214 | 18 |
| Operating Profit | 47 | 52 | 86 | 120 | 161 | 263 | -142 | -154 | -14 |
| OPM % | 20% | 18% | 18% | 17% | 14% | 16% | -9% | -255% | -476% |
| Other Income | 0 | 3 | 5 | 1 | 13 | 3 | -38 | -35 | 0 |
| Interest | 14 | 16 | 26 | 41 | 62 | 108 | 179 | 207 | 108 |
| Depreciation | 6 | 8 | 9 | 16 | 21 | 27 | 35 | 62 | 63 |
| Profit before tax | 27 | 30 | 56 | 64 | 90 | 132 | -393 | -459 | -185 |
| Tax % | 21% | 22% | 26% | 12% | 16% | 24% | -31% | -34% | |
| Net Profit | 21 | 24 | 42 | 56 | 76 | 100 | -273 | -302 | 259 |
| EPS in Rs | 16.37 | 28.83 | 38.80 | 52.57 | 5.20 | -13.47 | -14.89 | 12.76 | |
| Dividend Payout % | 0% | 0% | 3% | 3% | 3% | 3% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -34% | -62% | -178% | ||
| Compounded Profit Growth | % | % | % | 126% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | -24% | -51% | -294% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 14 | 14 | 14 | 14 | 19 | 20 | 20 |
| Reserves | 80 | 124 | 164 | 216 | 289 | 501 | 227 | -75 |
| Borrowings | 148 | 196 | 318 | 501 | 708 | 1,441 | 1,754 | 2,009 |
| Other Liabilities | 54 | 60 | 124 | 218 | 375 | 205 | 126 | 63 |
| Total Liabilities | 293 | 394 | 621 | 949 | 1,386 | 2,166 | 2,128 | 2,017 |
| Fixed Assets | 62 | 81 | 162 | 213 | 229 | 404 | 728 | 671 |
| CWIP | 31 | 61 | 30 | 88 | 199 | 232 | 7 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 | 26 | 34 | 16 |
| Other Assets | 200 | 251 | 429 | 648 | 953 | 1,504 | 1,358 | 1,323 |
| Total Assets | 293 | 394 | 621 | 949 | 1,386 | 2,166 | 2,128 | 2,017 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 24 | -5 | 68 | -8 | 165 | 69 | 386 | 166 |
| Cash from Investing Activity | -48 | -56 | -54 | -121 | -144 | -245 | -150 | -8 |
| Cash from Financing Activity | 61 | 25 | 13 | 103 | -11 | 174 | -241 | -160 |
| Net Cash Flow | 38 | -36 | 26 | -25 | 10 | -2 | -6 | -3 |
| Free Cash Flow | -24 | -62 | 9 | -133 | 18 | -165 | 262 | 157 |
| CFO/OP | 58% | 0% | 85% | 6% | 108% | 32% | -356% | -201% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77 | 95 | 62 | 69 | 49 | 66 | 53 | 1,363 |
| Inventory Days | 172 | 235 | 238 | 247 | 271 | 309 | 179 | 1,254 |
| Days Payable | 63 | 63 | 88 | 117 | 108 | 20 | 10 | 56 |
| Cash Conversion Cycle | 185 | 266 | 212 | 199 | 212 | 355 | 222 | 2,561 |
| Working Capital Days | 171 | 251 | 213 | 220 | 184 | 308 | 238 | 5,556 |
| ROCE % | 16% | 20% | 18% | 17% | 16% | -11% | -12% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 0.16
Book Value₹ -37.9
ROCE-11.8 %
ROE-294 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-178%
Compounded Profit Growth (TTM)126%
Standalone figures.
Valuation
Market capRs 3 Cr
Enterprise valueRs 1,429 Cr
Price to book0.01x
Price to sales0.37x
EV / sales183.39x
Price to cash flow0.04x
Earnings yield-22930.97%
Dividend yield99.96%
P/E, 3-year average3.12x
P/B, 3-year average0.69x
P/E, 5-year average3.23x
P/B, 5-year average0.68x
Profitability
Operating margin (excl. other income)16.45%
Operating margin (incl. other income)16.62%
EBITDA margin-10926.83%
Pre-tax margin-14208.47%
Net profit margin-8510.91%
Net margin, latest quarter-3902.33%
ROE24.34%
ROCE16.11%
ROA5.64%
ROE, 3-year average26.78%
ROCE, 3-year average16.94%
ROA, 3-year average6.43%
ROE, 5-year average25.47%
ROCE, 5-year average17.38%
ROA, 5-year average6.89%
ROIC (approx.)-35.71%
Tax rate23.95%
Other income / net worth0.51%
Growth
Sales growth (latest year)41.12%
Profit growth (latest year)31.69%
Sales CAGR, 3 years48.73%
Sales CAGR, 5 years46.33%
Profit CAGR, 3 years33.91%
Profit CAGR, 5 years36.30%
Sales growth QoQ-80.28%
Profit growth QoQ-105.42%
Sales growth YoY (latest quarter)-92.51%
Per share
EPS (TTM)Rs -34.40
EPS (latest year)Rs 5.20
EPS (latest quarter)Rs -0.87
EPS, 3-year averageRs 32.19
EPS, 5-year averageRs 28.35
Book value per shareRs 26.98
Sales per shareRs 0.40
Cash flow per shareRs 3.58
Free cash flow per shareRs 8.15
Dividend per share (latest year)Rs 0.15
Dividend per share, 3-year averageRs 0.95
Dividend per share, 5-year averageRs 0.96
Dividends
Dividend payout2.89%
Dividend payout, 3-year average2.95%
Dividend payout, 5-year average3.08%
Efficiency
Asset turnover0.74x
Fixed asset turnover3.96x
Inventory turnover1.22x
Inventory days299 days
Debtor days66 days
Debtors turnover5.50x
Creditor days56 days
Cash conversion cycle2561 days
Working capital days5556 days
Leverage
Total debtRs 1,441 Cr
Cash and bankRs 15 Cr
Net debtRs 1,426 Cr
Debt to equity2.77x
Interest coverage-4.73x
Owners' fund to total sources24.01%
Debt to assets66.54%
Cash flow
Cash from Operating Activity (latest year)Rs 69 Cr
Cash from Investing Activity (latest year)Rs -245 Cr
Cash from Financing Activity (latest year)Rs 174 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs 157 Cr
FCFE (approx.: FCF + change in debt)Rs 890 Cr
Sales to cash flow23.22x
Statement figures
Net sales (TTM)Rs 8 Cr
Net sales (latest year)Rs 1,600 Cr
Sales (latest quarter)Rs 0 Cr
Operating profit excl. other income (latest year)Rs 263 Cr
Operating profit (latest quarter)Rs -1 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs -851 Cr
PBDT (TTM)Rs -1,044 Cr
Profit before tax (TTM)Rs -1,107 Cr
Tax (latest year)Rs 32 Cr
Net profit (TTM)Rs -663 Cr
Net profit (latest year)Rs 100 Cr
Net profit (latest quarter)Rs -17 Cr
Depreciation (TTM)Rs 63 Cr
Depreciation (latest quarter)Rs 16 Cr
Interest (TTM)Rs 193 Cr
Cost of goods sold (latest year)Rs 1,272 Cr
Total expenditure (latest year)Rs 1,337 Cr
Total income (latest year)Rs 1,603 Cr
Share capitalRs 19 Cr
ReservesRs 501 Cr
Shareholders' fundsRs 520 Cr
Total assetsRs 2,166 Cr
Net blockRs 404 Cr
Capital work in progressRs 232 Cr
InvestmentsRs 26 Cr
ReceivablesRs 291 Cr
InventoryRs 1,041 Cr
Other liabilitiesRs 205 Cr
Shares outstanding (crore)19.28
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SURYAPHARM | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -40.0% | -2.8% | -37.2 pts |
| 1 month | -25.0% | -6.8% | -18.2 pts |
| 3 months | +50.0% | -7.6% | +57.6 pts |
| 6 months | -88.9% | +0.4% | -89.3 pts |
| 1 year | -83.3% | -9.9% | -73.4 pts |
| 2 years | -89.7% | -13.6% | -76.1 pts |
| 3 years | -90.0% | +14.2% | -104.2 pts |
| 5 years | -99.5% | +27.9% | -127.4 pts |
Red flags
F-score 3 of 8| explain | Receivables outrunning sales Receivables grew 90% vs sales +41% in 2013 |
| explain | Share dilution Share count up 1230% in a year, 1230% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2014Sales ₹0 Cr -100.0% vs Dec 2013.
Net loss ₹17 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2014-11-25 | Annual General Meeting | |
| 2013-09-26 | Annual General Meeting | |
| 2012-09-25 | Annual General Meeting | |
| 2011-09-27 | Annual General Meeting And Dividend Re.0.15 Per Share | |
| 2010-12-23 | Face Value Split From Rs.10/- To Re.1/- | 0.1000 |
| 2010-09-27 | Annual General Meeting And Final Dividend Rs.1.50 Per Share | |
| 2009-09-16 | Dividend-Rs.1.20 Pr Share | |
| 2008-09-17 | Agm/Dividend - 10% | |
| 2007-09-12 | Agm | |
| 2006-09-27 | Agm |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Surya Pharmaceutical Ltd?
Surya Pharmaceutical Ltd (SURYAPHARM) has a market capitalisation of Rs Cr. at the 2015-09-14 close.
What were Surya Pharmaceutical Ltd's latest quarterly results?
In the Dec 2014 quarter, Surya Pharmaceutical Ltd sales was Rs 0 Cr (-100.0% vs Dec 2013) with a net loss of Rs 17 Cr.